Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy does not list increased libido as a recognised side effect, and no clinical trial data shows semaglutide directly raises sexual desire. That said, many people do report shifts in how they feel about sex while on treatment, and the reasons are real, if indirect. These medicines are prescription-only and require a clinical assessment before a prescriber considers them suitable for you.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The short answer is no, not in any direct, pharmacological sense. Semaglutide works by activating GLP-1 receptors involved in appetite signalling and blood-sugar regulation. It slows gastric emptying and reduces hunger; it does not act on the hormonal pathways that govern libido. The STEP 1 trial published in the New England Journal of Medicine, which tracked nearly 2,000 adults on semaglutide 2.4mg for 68 weeks, did not find increased sexual desire as a side effect in either direction.
A question our prescribers hear most weeks, though, is some version of this: "I feel more interested in sex since starting Wegovy, is that the injection?" It is a fair thing to notice and worth exploring, because the answer is almost certainly yes, just not in the way people assume.
What changes is not your biochemistry in the direct sense. What changes is your body, your energy, your relationship with yourself, and those things have a lot to do with desire. The medicine is the vehicle; the effect on libido comes through what the medicine does over time, not through a chemical signal it sends directly.
Significant weight loss reliably improves sexual function and confidence for many people. Research in this area is consistent: excess weight is associated with lower testosterone in men, disrupted oestrogen levels, reduced physical stamina and poorer body image, all of which suppress desire. As weight falls, those factors shift. Hormonal balance can improve. Physical activity becomes easier. Energy returns.
There is also the psychological dimension. Feeling better in your body tends to translate into feeling more present in intimate situations. That is not trivial, and it is not placebo, it is a well-documented consequence of meaningful, sustained weight loss. The NHS patient information for semaglutide focuses on the physical side-effect profile, but the broader picture of how people feel on treatment is more nuanced than a list of gastrointestinal symptoms.
On the other side of the ledger: in the early weeks of treatment, nausea, fatigue and gastrointestinal discomfort are common. These can absolutely dampen libido, and that is normal. Some people also ask whether Wegovy makes you hot or causes temperature-related symptoms, which is another way the body can feel unsettled during adjustment. For most people these symptoms ease as the body adjusts, typically within the first few weeks of each dose stage. If fatigue or low mood persist rather than settle, that is worth discussing with a prescriber.
For some people, yes, at least temporarily. The gastrointestinal side effects of semaglutide (nausea, bloating, indigestion) are well-documented and for some are significant, particularly after a dose increase. Feeling unwell is not a condition under which most people feel desire. Similarly, if weight loss is happening faster than expected and calorie intake has dropped sharply, fatigue can become a factor.
Mood changes are also worth mentioning. There is an open question about GLP-1 medicines and mood that researchers are actively investigating. The MHRA monitors this and has not issued a formal causal finding, but anyone noticing low mood, emotional flatness or changes in mental wellbeing on Wegovy should contact their prescriber. Do not wait for a scheduled check-in if something feels off.
The practical picture, then, is that libido on Wegovy is shaped by where you are in treatment: early weeks can bring suppression via nausea and fatigue; over months, as weight falls and wellbeing improves, the trend for most people is upward. Individual experience varies considerably. If you want to understand more about how Wegovy affects how you feel day to day, that page covers the full picture.
Mention it to your prescriber. Changes in libido can reflect a range of things, hormonal shifts from weight loss, mood changes, medication effects, or simply the stress and adjustment of being on a new treatment. A prescriber can help identify which, and whether anything needs to be reviewed. This is not an embarrassing conversation; it is a clinical one, and it matters for your wellbeing.
If you are considering Wegovy and wondering how it might affect your daily life more broadly, the Wegovy information page covers the treatment in full, including how to access it through a clinician-led service. For cost context, the guide to Wegovy pricing in the UK explains what legitimate private treatment typically involves. And if you want to explore whether you might be suitable, check your eligibility with our prescribers, consultations are free, and a real clinician reviews every application the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.